Cargando…

Clinical benefits of oral anticoagulants in atrial fibrillation patients with dementia: a systematic review and meta-analysis

BACKGROUND: The management of atrial fibrillation (AF) with oral anticoagulants (OAC) is generally recommended to reduce the risk of stroke. However, the decision to prescribe these medications for patients with AF and dementia remains controversial. METHODS: A systematic review and meta-analysis of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Dayang, Xu, Xiaoqing, Han, Xiaowan, Xie, Jing, Zhou, Hufang, Peng, Wenhua, Pan, Guozhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507720/
https://www.ncbi.nlm.nih.gov/pubmed/37731522
http://dx.doi.org/10.3389/fcvm.2023.1265331
_version_ 1785107374117224448
author Wang, Dayang
Xu, Xiaoqing
Han, Xiaowan
Xie, Jing
Zhou, Hufang
Peng, Wenhua
Pan, Guozhong
author_facet Wang, Dayang
Xu, Xiaoqing
Han, Xiaowan
Xie, Jing
Zhou, Hufang
Peng, Wenhua
Pan, Guozhong
author_sort Wang, Dayang
collection PubMed
description BACKGROUND: The management of atrial fibrillation (AF) with oral anticoagulants (OAC) is generally recommended to reduce the risk of stroke. However, the decision to prescribe these medications for patients with AF and dementia remains controversial. METHODS: A systematic review and meta-analysis of retrospective cohort studies were conducted. The search encompassed PubMed, Cochrane Library, Web of Science, and Embase databases from inception until May 1st, 2023, with language limited to English. Eligible studies included comparisons between exposure to OAC vs. non-OAC in the AF population with dementia or cognitive impairment. Studies that compared the effects of direct oral anticoagulants (DOAC) and vitamin-K antagonists were also included. The primary outcome was all-cause mortality, and the secondary outcomes were ischemic stroke and major bleeding. This study was registered with PROSPERO (No. CRD42023420678). RESULTS: A total of five studies (N = 21,962 patients) met the eligibility criteria and were included in this review. The follow-up duration ranged from 1 to 4 years. Meta-analysis demonstrated that OAC treatment was associated with a lower risk of all-cause mortality in AF patients with dementia with a hazard ratio (HR) of 0.79 and a 95% confidence interval (CI) ranging from 0.68 to 0.92, compared to non-OAC treatment. No statistical differences were observed in the risk of major bleeding (HR = 1.12, 95% CI: 0.88–1.42) or ischemic stroke (HR = 0.77, 95% CI: 0.58–1.00). Three studies reported comparisons between DOAC and warfarin; however, pooled analysis was not performed due to heterogeneity. CONCLUSION: The use of OACs in individuals diagnosed with both AF and dementia holds the potential to reduce all-cause mortality rates, thereby improving the overall clinical prognosis within this specific population. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023420678, PROSPERO identifier, CRD42023420678.
format Online
Article
Text
id pubmed-10507720
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105077202023-09-20 Clinical benefits of oral anticoagulants in atrial fibrillation patients with dementia: a systematic review and meta-analysis Wang, Dayang Xu, Xiaoqing Han, Xiaowan Xie, Jing Zhou, Hufang Peng, Wenhua Pan, Guozhong Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: The management of atrial fibrillation (AF) with oral anticoagulants (OAC) is generally recommended to reduce the risk of stroke. However, the decision to prescribe these medications for patients with AF and dementia remains controversial. METHODS: A systematic review and meta-analysis of retrospective cohort studies were conducted. The search encompassed PubMed, Cochrane Library, Web of Science, and Embase databases from inception until May 1st, 2023, with language limited to English. Eligible studies included comparisons between exposure to OAC vs. non-OAC in the AF population with dementia or cognitive impairment. Studies that compared the effects of direct oral anticoagulants (DOAC) and vitamin-K antagonists were also included. The primary outcome was all-cause mortality, and the secondary outcomes were ischemic stroke and major bleeding. This study was registered with PROSPERO (No. CRD42023420678). RESULTS: A total of five studies (N = 21,962 patients) met the eligibility criteria and were included in this review. The follow-up duration ranged from 1 to 4 years. Meta-analysis demonstrated that OAC treatment was associated with a lower risk of all-cause mortality in AF patients with dementia with a hazard ratio (HR) of 0.79 and a 95% confidence interval (CI) ranging from 0.68 to 0.92, compared to non-OAC treatment. No statistical differences were observed in the risk of major bleeding (HR = 1.12, 95% CI: 0.88–1.42) or ischemic stroke (HR = 0.77, 95% CI: 0.58–1.00). Three studies reported comparisons between DOAC and warfarin; however, pooled analysis was not performed due to heterogeneity. CONCLUSION: The use of OACs in individuals diagnosed with both AF and dementia holds the potential to reduce all-cause mortality rates, thereby improving the overall clinical prognosis within this specific population. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023420678, PROSPERO identifier, CRD42023420678. Frontiers Media S.A. 2023-09-05 /pmc/articles/PMC10507720/ /pubmed/37731522 http://dx.doi.org/10.3389/fcvm.2023.1265331 Text en © 2023 Wang, Xu, Han, Xie, Zhou, Peng and Pan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Wang, Dayang
Xu, Xiaoqing
Han, Xiaowan
Xie, Jing
Zhou, Hufang
Peng, Wenhua
Pan, Guozhong
Clinical benefits of oral anticoagulants in atrial fibrillation patients with dementia: a systematic review and meta-analysis
title Clinical benefits of oral anticoagulants in atrial fibrillation patients with dementia: a systematic review and meta-analysis
title_full Clinical benefits of oral anticoagulants in atrial fibrillation patients with dementia: a systematic review and meta-analysis
title_fullStr Clinical benefits of oral anticoagulants in atrial fibrillation patients with dementia: a systematic review and meta-analysis
title_full_unstemmed Clinical benefits of oral anticoagulants in atrial fibrillation patients with dementia: a systematic review and meta-analysis
title_short Clinical benefits of oral anticoagulants in atrial fibrillation patients with dementia: a systematic review and meta-analysis
title_sort clinical benefits of oral anticoagulants in atrial fibrillation patients with dementia: a systematic review and meta-analysis
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507720/
https://www.ncbi.nlm.nih.gov/pubmed/37731522
http://dx.doi.org/10.3389/fcvm.2023.1265331
work_keys_str_mv AT wangdayang clinicalbenefitsoforalanticoagulantsinatrialfibrillationpatientswithdementiaasystematicreviewandmetaanalysis
AT xuxiaoqing clinicalbenefitsoforalanticoagulantsinatrialfibrillationpatientswithdementiaasystematicreviewandmetaanalysis
AT hanxiaowan clinicalbenefitsoforalanticoagulantsinatrialfibrillationpatientswithdementiaasystematicreviewandmetaanalysis
AT xiejing clinicalbenefitsoforalanticoagulantsinatrialfibrillationpatientswithdementiaasystematicreviewandmetaanalysis
AT zhouhufang clinicalbenefitsoforalanticoagulantsinatrialfibrillationpatientswithdementiaasystematicreviewandmetaanalysis
AT pengwenhua clinicalbenefitsoforalanticoagulantsinatrialfibrillationpatientswithdementiaasystematicreviewandmetaanalysis
AT panguozhong clinicalbenefitsoforalanticoagulantsinatrialfibrillationpatientswithdementiaasystematicreviewandmetaanalysis